Francisco Fonseca - Academia.edu (original) (raw)
Uploads
Papers by Francisco Fonseca
Atherosclerosis Supplements, 2009
Arquivos Brasileiros de Cardiologia
Journal of the American College of Cardiology
Journal of Clinical Lipidology, Jan 5, 2014
Obesity is associated with several cardiovascular risk factors, including nonalcoholic fatty live... more Obesity is associated with several cardiovascular risk factors, including nonalcoholic fatty liver disease (NAFLD). These risk factors can induce changes in the arteries such as an increase in the carotid intima-media thickness (cIMT), which contributes to the early development of atherosclerosis. To determine whether NAFLD is associated with an atherogenic lipid profile, inflammatory markers, or cIMT in obese adolescents and to compare the effects of therapeutic lifestyle changes in NAFLD and non-NAFLD groups. A total of 79 obese adolescents were divided into two groups: 33 NAFLD and 46 non-NAFLD. They were submitted to an interdisciplinary therapy involving diet exercise and psychological support during the course of 1 year. The cIMT and estimates of fat mass (liver, intra-abdominal, and subcutaneous) were determined ultrasonographically. Body composition, glucose, lipid profile, and adipokines were analyzed before and after the therapy. At baseline, only in the NAFLD group was the homeostasis model assessment of insulin resistance positively correlated with cIMT and triglyceride/high-density lipoprotein cholesterol ratio. Therapy was associated with an increase in adiponectin concentrations and reduced visceral fat, cIMT, leptin, and plasminogen activator inhibitor-1 concentrations, as well as the ratios of total cholesterol/high-density lipoprotein cholesterol and triglycerides/high-density lipoprotein cholesterol in both groups. Only in the non-NAFLD group did therapy result in a reduction in the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and increased high-density lipoprotein cholesterol concentration. In obese adolescents, NAFLD is associated with cardiovascular risk factors and inflammatory markers of atherosclerosis that were positively correlated with cIMT only in the NAFLD group. Nevertheless, the strength of the present study is that the interdisciplinary therapy effectively improved cIMT and other proinflammatory adipokines in both groups.
Atherosclerosis Supplements, 2009
![Research paper thumbnail of [Statins and stroke: potential mechanisms for neurovascular protection]](https://attachments.academia-assets.com/83595897/thumbnails/1.jpg)
](Revista de neurologia, 2010
As the average human lifespan is increasing worldwide, ischemic stroke became one of the most imp... more As the average human lifespan is increasing worldwide, ischemic stroke became one of the most important causes of mortality and morbidity, particularly in emerging countries. Significant decrease in the rates of first and recurrent stroke using statins has been established in large clinical trials and in systematic reviews and meta-analyses. Interestingly, observational studies reported that cholesterol levels were only weakly associated with ischemic stroke, suggesting that other potential mechanisms for vascular protection should be implicated. Indeed, beyond lipid changes, some properties of these drugs, related to inflammation, hemostasis, endothelial function, plaque stabilization, and more recently, to the mobilization of endothelial cells, have been proposed. In addition, recent meta-analysis also revealed that statins decrease systolic and diastolic blood pressure. Taken together, all these benefits can contribute for stroke prevention by statins.
Arquivos brasileiros de cardiologia, 1994
To evaluate the effects of pravastatin on lipoproteins, Lp (a), apo B and apo A-I and its tolerab... more To evaluate the effects of pravastatin on lipoproteins, Lp (a), apo B and apo A-I and its tolerability in primary hypercholesterolemic patients in our outpatient lipid clinic. Twenty-two primary hypercholesterolemic patients were evaluated. They had all been treated previously with other hypocholesterolemic drugs, including the statins, forming a specific and homogeneous group with hypercholesterolemia and definite coronary risk. After 7 weeks with American Heart Association phase I diet and placebo drug, pravastatin was administered during 12 weeks. All patients received an initial daily dose of 10 mg for six weeks. After this period, this dose was increased to 20 mg. The levels of cholesterol, triglycerides, high-density lipoprotein, lipoprotein (a) and apolipoproteins A-1 and B were determined. No changes occurred with diet and placebo, but pravastatin at a daily dose of 10 mg, reduced significantly cholesterol level (7.22%), LDL-cholesterol (13.08%) and increased HDL-cholesterol...
Atherosclerosis Supplements, 2010
Atherosclerosis Supplements, 2010
Atherosclerosis Supplements, 2009
Arquivos Brasileiros de Cardiologia
Journal of the American College of Cardiology
Journal of Clinical Lipidology, Jan 5, 2014
Obesity is associated with several cardiovascular risk factors, including nonalcoholic fatty live... more Obesity is associated with several cardiovascular risk factors, including nonalcoholic fatty liver disease (NAFLD). These risk factors can induce changes in the arteries such as an increase in the carotid intima-media thickness (cIMT), which contributes to the early development of atherosclerosis. To determine whether NAFLD is associated with an atherogenic lipid profile, inflammatory markers, or cIMT in obese adolescents and to compare the effects of therapeutic lifestyle changes in NAFLD and non-NAFLD groups. A total of 79 obese adolescents were divided into two groups: 33 NAFLD and 46 non-NAFLD. They were submitted to an interdisciplinary therapy involving diet exercise and psychological support during the course of 1 year. The cIMT and estimates of fat mass (liver, intra-abdominal, and subcutaneous) were determined ultrasonographically. Body composition, glucose, lipid profile, and adipokines were analyzed before and after the therapy. At baseline, only in the NAFLD group was the homeostasis model assessment of insulin resistance positively correlated with cIMT and triglyceride/high-density lipoprotein cholesterol ratio. Therapy was associated with an increase in adiponectin concentrations and reduced visceral fat, cIMT, leptin, and plasminogen activator inhibitor-1 concentrations, as well as the ratios of total cholesterol/high-density lipoprotein cholesterol and triglycerides/high-density lipoprotein cholesterol in both groups. Only in the non-NAFLD group did therapy result in a reduction in the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and increased high-density lipoprotein cholesterol concentration. In obese adolescents, NAFLD is associated with cardiovascular risk factors and inflammatory markers of atherosclerosis that were positively correlated with cIMT only in the NAFLD group. Nevertheless, the strength of the present study is that the interdisciplinary therapy effectively improved cIMT and other proinflammatory adipokines in both groups.
Atherosclerosis Supplements, 2009
Revista de neurologia, 2010
As the average human lifespan is increasing worldwide, ischemic stroke became one of the most imp... more As the average human lifespan is increasing worldwide, ischemic stroke became one of the most important causes of mortality and morbidity, particularly in emerging countries. Significant decrease in the rates of first and recurrent stroke using statins has been established in large clinical trials and in systematic reviews and meta-analyses. Interestingly, observational studies reported that cholesterol levels were only weakly associated with ischemic stroke, suggesting that other potential mechanisms for vascular protection should be implicated. Indeed, beyond lipid changes, some properties of these drugs, related to inflammation, hemostasis, endothelial function, plaque stabilization, and more recently, to the mobilization of endothelial cells, have been proposed. In addition, recent meta-analysis also revealed that statins decrease systolic and diastolic blood pressure. Taken together, all these benefits can contribute for stroke prevention by statins.
Arquivos brasileiros de cardiologia, 1994
To evaluate the effects of pravastatin on lipoproteins, Lp (a), apo B and apo A-I and its tolerab... more To evaluate the effects of pravastatin on lipoproteins, Lp (a), apo B and apo A-I and its tolerability in primary hypercholesterolemic patients in our outpatient lipid clinic. Twenty-two primary hypercholesterolemic patients were evaluated. They had all been treated previously with other hypocholesterolemic drugs, including the statins, forming a specific and homogeneous group with hypercholesterolemia and definite coronary risk. After 7 weeks with American Heart Association phase I diet and placebo drug, pravastatin was administered during 12 weeks. All patients received an initial daily dose of 10 mg for six weeks. After this period, this dose was increased to 20 mg. The levels of cholesterol, triglycerides, high-density lipoprotein, lipoprotein (a) and apolipoproteins A-1 and B were determined. No changes occurred with diet and placebo, but pravastatin at a daily dose of 10 mg, reduced significantly cholesterol level (7.22%), LDL-cholesterol (13.08%) and increased HDL-cholesterol...
Atherosclerosis Supplements, 2010
Atherosclerosis Supplements, 2010